Disposition and metabolism of the colchicine derivative [¹⁴C]-ZD6126 in rat and dog

References

• Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: A novel small molecule vascular targeting agent. International Journal of Radiation, Oncology, Biology, Physics 2002b; 54(5)1497–1502
   PubMed Web of Science ®Google Scholar
• Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. Antitumour activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clinical Cancer Research 2002a; 8: 1974–1983
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. British Journal of Cancer 1999; 80(Suppl. 1)57–64
   PubMed Web of Science ®Google Scholar
• D'Souza RA, Partridge EA, Roberts DW, Ashton S, Ryan A, Patterson AB, Wilson Z, Thurrell CC. The distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour bearing mice. Xenobiotica 2007; 37(3)328–340
   PubMed Web of Science ®Google Scholar
• Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Research 2002; 62: 7247–7253
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, LoRusso P, Morton P, Wheeler C, Barge A, Evelhoch J. MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature. abst 440. 2002, Proceedings of the American Society of Clinical Oncology 21
   Google Scholar
• Gibson G, Skett P. Introduction to drug metabolism (Cheltenham: Nelson Thornes) 2001
   Google Scholar
• Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. British Journal of Cancer 1999; 81: 1318–1827
   PubMed Web of Science ®Google Scholar
• Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: Anti-vascular effects in a murine tumour. European Journal of Cancer 1993; 29A: 1320–1324
   PubMed Web of Science ®Google Scholar
• Hunter AL, Klaassen CD. Biliary excretion of colchicine. Journal of Pharmacology and Experimental Therapeutics 1974; 192(3)605–617
   Google Scholar
• Judson I, Scurr M, Roberts DW, Partridge EA, D'Souza RA, Tan S. Pharmacokinetics and metabolism of ZD6126 in patients with solid tumours (in preparation) 2008
   Google Scholar
• Legraverend C, Mode A, Westin S, Strom A, Eguchi H, Zaphiropoulos PG, Gustafsson JA. Transcriptional regulation of rat P-450 2C gene subfamily members by the sexually dimorphic pattern of growth hormone secretion. Molecular Endocrinology 1992; 6: 259–266
   PubMed Web of Science ®Google Scholar
• Lenz EM, D'Souza RA, Jordan AC, King CD, Smith SM, Phillips PJ, McCormick AD, Roberts DW. HPLC-NMR with severe column overloading: Fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126. Journal of Pharmaceutical and Biomedical Analysis 2007; 43: 1065–1077
   PubMedGoogle Scholar
• McCormick AD, Slamon DL, Lenz EM, King CD, Phillips PJ, McKillop D, Roberts DW. In vitro metabolism of M445526 (ZD6126 phenol) in human liver microsomes and hepatocytes. Xenobiotica 2007; 37(9)972–985
   PubMed Web of Science ®Google Scholar
• McKillop D, Partridge EA, Hutchison M, Rhead SA, Parry AC, Bardsley J, Woodman HM, Swaisland HC. Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica 2004; 34: 901–915
   PubMed Web of Science ®Google Scholar
• Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research 2003; 63: 1534–1537
   PubMed Web of Science ®Google Scholar
• Radema SA, Beerepoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE. Clinical evaluation of the novel vascular-targeting agent, ZD6126: Assessment of toxicity and surrogate markers of vascular damage. Proceedings of the American Society of Clinical Oncology 21:abst 439 2002
   Google Scholar
• Sandoval IV, Weber K. Polymerization of tubulin in the presence of colchicine or podophyllotoxin. Formation of a ribbon structure induced by guanylyl-5′-methylene diphosphonate. Journal of Molecular Biology 1979; 134: 159–172
   PubMedGoogle Scholar
• Scurr M, Judson I, Brock C, O’Donnell A, Tan S, Partridge EA, D'Souza RA, Roberts D. Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumours. Journal of Clinical Oncology 2004, ASCO Annual Meeting Proceedings 22 (145):3083 (abst)
   Google Scholar
• Skett P. Role of hormones in the control of mixed function oxidases. Biochemical Society Transactions 1990; 18(1)24–26
   PubMedGoogle Scholar
• Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochemical Pharmacology 1997; 53: 111–116
   PubMed Web of Science ®Google Scholar
• Tomer G, Ananthanarayanan M, Weymann A, Balasubra-manian N, Suchy FJ. Differential developmental regulation of rat liver canalicular membrane transporters Bsep and Mrp2. Pediatric Research 2003; 53(2)288–294
   PubMedGoogle Scholar
• Walaszek EJ, Kocsis JJ, Leroy GV, Geiling EMK. Studies on the excretion of radioactive colchicine. Archives Internationales de Pharmacodynamie et de Therapie 1960; 125: 371–382
   Google Scholar
• Waxman DJ, Ram PA, Notani G, LeBlanc GA, Alberta JA, Morrissey JJ, Sundseth SS. Pituitary regulation of the male-specific steroid 6 beta-hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppressive influence of growth hormone and thyroxine acting at a pretranslational level. Molecular Endocrinology 1990; 4: 447–454
   PubMed Web of Science ®Google Scholar